As US measles cases rise, biotech firms start developing new treatments
Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection.
Reported by 1 outlet — Ars Technica. See all sources ↓
Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these countermeasures are available, and it’s even more uncertain if those who refuse vaccines would take such treatments. Fueled by large outbreaks in South Carolina and Utah, the US had already surpassed last year’s 2,289 measles cases, and it’s only July.
Read the full report at Ars Technica ↗
Why it matters
A technology story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 23h ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
As US measles cases rise, biotech firms start developing new treatments
Sources1TypeCoverageArs Technica